Progress in mechanism and targeted therapy of immune kidney disease mediated by complement
YU Jianmei
HE Weichun
Abstract：Atypical hemolytic uremic syndrome(aHUS)and C3 glomerulopathy(C3G)are well-recognized complement-mediated kidney diseases.In recent years,an increasing body of evidence has demonstrated that the complement system plays a pivotal role in the pathogenesis of various immune-mediated kidney diseases,such as IgA nephropathy,membranous nephropathy(MN),lupus nephritis(LN),antineutrophil cytoplasmic antibody-associated vasculitis(AAV),and anti-glomerular basement membrane disease(anti-GBM disease).Although current immunosuppressive therapies and corticosteroids can partly control disease progression,these agents are frequently associated with severe adverse effects,and a portion of patients show suboptimal therapeutic responses.Therefore,the development of novel therapeutic strategies is an urgent necessity.Complement-targeted therapies have emerged as a research focus,providing new avenues for the treatment of immune-mediated kidney diseases.This review summarizes recent advancements in this field.
Keywords：complement systemglomerulonephritisautoimmune kidney diseasecomplement inhibitors
Publication Date：2026-03-10
Online Publishing Date：2026-03-20(First online date of this platform, not the publication date of the document)
Pages：10( 899-908 )